Moderna outlines $80B market

Moderna has vaccines in development to take on a combined $80 billion (US$52 billion) market for infectious diseases, the mRNA giant told its fifth annual Vaccines and Business Update, and although it might be late to the RSV party, it's thrown down the gauntlet to rivals.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here